Brimonidine Tartrate; Carbachol Patent Expiration

Brimonidine Tartrate; Carbachol was first introduced by Visus Therapeutics Inc in its drug Yuvezzi on Jan 28, 2026.


Brimonidine Tartrate; Carbachol Patents

Given below is the list of patents protecting Brimonidine Tartrate; Carbachol, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Yuvezzi US12268662 Formulations Comprising Carbachol And Brimonidine To Enhance Anti- Presbyopia Effects Nov 10, 2042 Visus
Yuvezzi US8455494 Preparations And Methods For Ameliorating Or Reducing Presbyopia May 24, 2030 Visus



Brimonidine Tartrate; Carbachol's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Brimonidine Tartrate; Carbachol Generic API Manufacturers

Given below is the list of companies who have filed for Brimonidine Tartrate; Carbachol generic, along with the locations of their manufacturing plants worldwide.